0.00Open12.85Pre Close0 Volume2 Open Interest60.00Strike Price0.00Turnover61.18%IV7.30%PremiumDec 20, 2024Expiry Date7.90Intrinsic Value100Multiplier7DDays to Expiry4.96Extrinsic Value100Contract SizeAmericanOptions Type0.9319Delta0.0227Gamma8.43Leverage Ratio-0.0580Theta0.0107Rho7.86Eff Leverage0.0124Vega
Equity Lifestyle Properties Inc Stock Discussion
Gap Ups
1. $Zions Bancorp (ZION.US)$ - up 4.0%
2. $Equity Lifestyle Properties Inc (ELS.US)$ - up 3.6%
3. $Novo-Nordisk A/S (NVO.US)$ - up 1.7%
4. $Freeport-McMoRan (FCX.US)$ - up 1.4%
5. $Orange SA (ORAN.US)$ - up 0.9%
6. $Sanofi (SNY.US)$ - up 0.9%
7. $Catalent (CTLT.US)$ - up 0.9%
8. $Tenaris (TS.US)$ - up 0.9...
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Arcturus Therapeutics (ARCT.US)$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals (ARWR.US)$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group (CRON.US)$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair (DINO.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8 (EGHT.US)$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta (NOVT.US)$ : William...
• $Checkmate Pharmaceuticals (CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics (AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer (SMCI.US)$ +14.3% (earnings report)
• $Plug Power (PLUG.US)$ +9.24% (t...
No comment yet